129 related articles for article (PubMed ID: 33652026)
1. Management Trends in Pediatric Nonseminomatous Germ Cell Tumors.
Koehne EL; Patel PM; Patel HD; Srivastava A; Slovacek H; Gupta GN; Woods ME; Bowen DK
Urology; 2021 Oct; 156():238-244. PubMed ID: 33652026
[TBL] [Abstract][Full Text] [Related]
2. Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database.
Weiner AB; Pearce SM; Eggener SE
Cancer; 2017 Jan; 123(2):245-252. PubMed ID: 27626903
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy analysis of three therapeutic modes on clinical stage Ia nonseminomatous germ cell testicular tumors].
Dong P; Liu ZW; Li XD; Wu S; Li YH; Yao K; Qin ZK; Han H; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2013 Mar; 51(3):256-60. PubMed ID: 23859330
[TBL] [Abstract][Full Text] [Related]
4. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
[TBL] [Abstract][Full Text] [Related]
5. Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle.
Ghandour R; Ashbrook C; Freifeld Y; Singla N; El-Asmar JM; Lotan Y; Margulis V; Eggener S; Woldu S; Bagrodia A
Eur Urol Oncol; 2020 Apr; 3(2):198-206. PubMed ID: 31272940
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.
Hamilton RJ; Nayan M; Anson-Cartwright L; Atenafu EG; Bedard PL; Hansen A; Chung P; Warde P; Sweet J; O'Malley M; Sturgeon J; Jewett MAS
J Clin Oncol; 2019 Aug; 37(22):1919-1926. PubMed ID: 30802156
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
8. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
9. Surveillance alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis (NSGCT).
Sogani PC; Fair WR
Semin Urol; 1988 Feb; 6(1):53-6. PubMed ID: 2838876
[No Abstract] [Full Text] [Related]
10. The management of stage I nonseminomatous testicular germ cell tumors.
Pectasides D; Farmakis D; Pectasides M
Oncology; 2006; 71(3-4):151-8. PubMed ID: 17646698
[TBL] [Abstract][Full Text] [Related]
11. Survival of nonseminomatous germ cell tumors in pediatric patients and young adults - A stage group stratified analysis.
Srivastava A; Patel HV; Koehne E; Gupta GN; Drachtman R; Pierorazio PM; Bagrodia A; Elsamra SE; Kim IY; Ghodoussipour S; Singer EA; Jang TL; Patel HD; Barone JG
Urol Oncol; 2022 Apr; 40(4):169.e1-169.e12. PubMed ID: 35144865
[TBL] [Abstract][Full Text] [Related]
12. [A clinical study of testicular tumors].
Matsuki H; Ozono S; Arai K; Saka M; Cho M; Nakagawa Y; Kaneko Y; Yoshida K; Okamoto S; Maruyama Y
Hinyokika Kiyo; 1988 Oct; 34(10):1757-65. PubMed ID: 2854363
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.
Gumus M; Bilici A; Odabas H; Ustaalioglu BBO; Kandemir N; Demirci U; Cihan S; Bayoglu IV; Ozturk T; Turkmen E; Urakci Z; Seker MM; Gunaydin Y; Selcukbiricik F; Turan N; Sevinc A
World J Urol; 2017 Jul; 35(7):1103-1110. PubMed ID: 27812752
[TBL] [Abstract][Full Text] [Related]
14. Current management of stage I testicular germ cell tumors in a French cancer institute. A practice analysis over the 10 past years.
Chanal E; Bouleftour W; Guillot A; Rowinski E; Bernichon E; Tremeau L; Lardon R; Lacroix B; Lorin S; Delorme G; Perraud Y; Armand C; Levigne F; Vallard A; Langrand-Escure J; Fournel P; Benoite M; Vassal C
Bull Cancer; 2019 Dec; 106(12):1086-1093. PubMed ID: 31582176
[TBL] [Abstract][Full Text] [Related]
15. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
16. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
17. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
Ondrus D; Ondrusova M; Hornak M; Matoska J
Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
[TBL] [Abstract][Full Text] [Related]
18. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.
Fizazi K; Oldenburg J; Dunant A; Chen I; Salvioni R; Hartmann JT; De Santis M; Daugaard G; Flechon A; de Giorgi U; Tjulandin S; Schmoll HJ; Bouzy J; Fossa SD; Fromont G
Ann Oncol; 2008 Feb; 19(2):259-64. PubMed ID: 18042838
[TBL] [Abstract][Full Text] [Related]
19. Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy.
Mazzone E; Mistretta FA; Knipper S; Tian Z; Palumbo C; Gandaglia G; Soulieres D; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2019 Dec; 17(6):e1153-e1162. PubMed ID: 31515197
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
